Edition:
India

Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

0.97USD
7 Dec 2018
Change (% chg)

$-0.07 (-6.63%)
Prev Close
$1.04
Open
$1.04
Day's High
$1.04
Day's Low
$0.97
Volume
24,402
Avg. Vol
89,302
52-wk High
$123.00
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Aytu BioScience Says On Nov 29, Issued A Secured, Non-Convertible $5 Mln Promissory Note (Armistice Note) To Armistice Capital
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Aytu BioScience Inc ::AYTU BIOSCIENCE INC - ON NOVEMBER 29, ISSUED A SECURED, NON-CONVERTIBLE $5.0 MILLION PROMISSORY NOTE ( ARMISTICE NOTE ) TO ARMISTICE CAPITAL - SEC FILING.AYTU BIOSCIENCE INC - ON NOVEMBER 30, 2018, EXPANDED SIZE OF BOARD OF DIRECTORS BY TWO SEATS.AYTU BIOSCIENCE INC - ELECTED KETAN B. MEHTA AS A DIRECTOR.AYTU BIOSCIENCE INC - ANTICIPATES THAT BOARD OF DIRECTORS WILL ELECT STEVEN J. BOYD TO FILL REMAINING VACANCY IN Q1 OF 2019.  Full Article

Bigger Capital Fund Reports 7.4 Pct Passive Stake In Aytu Bioscience As Of March 2
Friday, 9 Mar 2018 

March 8 (Reuters) - Aytu Bioscience Inc ::BIGGER CAPITAL FUND L P REPORTS A 7.4 PERCENT PASSIVE STAKE IN AYTU BIOSCIENCE INC AS OF MARCH 2 - SEC FILING.  Full Article

Acerus Pharmaceuticals Announces C$1.6 Million Worth Purchase Orders
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Acerus Pharmaceuticals Corporation ::ACERUS PHARMACEUTICALS - ANNOUNCED C$1.6 MILLION WORTH OF NATESTO PURCHASE ORDERS FROM ITS U.S. LICENSEE AYTU BIOSCIENCE.  Full Article

Aytu Bioscience files for mixed shelf of upto $100 mln
Thursday, 23 Nov 2017 

Nov 22 (Reuters) - Aytu Bioscience Inc :Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing.  Full Article

Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aytu Bioscience Inc ::Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system for male infertility.Aytu Bioscience Inc - ‍expects to announce a distribution partner and launch Mioxsys for clinical use in coming quarters​.Aytu Bioscience Inc - ‍has engaged in australian market development activities and is in early discussions with distribution partners​.Aytu Bioscience - ‍Mioxsys been approved by TGA as an aid in diagnostic assessment of semen quality for patients undergoing male infertility evaluation​.  Full Article

Aytu Bioscience CFO Gregory Gould resigns
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Aytu Bioscience Inc :Aytu Bioscience Inc - ‍on October 26, 2017, Gregory A. Gould resigned as Chief Financial Officer​.Aytu Bioscience Inc - ‍Gould's resignation will become effective on November 15, 2017 -​ SEC filing.  Full Article